Table 2.

Inhibitors of nuclear export tested in humans

Drug	Parent company	Molecular Target	Trial phase	Indication for human use	Clinical trials.gov Identifier(s)
First generation nuclear export inhibitor
Leptomycin (also called elactocin)	Warner-Lambert	Exportin-1	1	Advanced refractory solid cancers
Second generation nuclear export inhibitors
SL-801	Stemline Therapeutics, Inc.	Exportin-1	1	Advanced Solid Tumors	NCT02667873
Selinexor (KPT-330)	Karyopharm Therapeutics, Inc	Exportin-1	2/3	Acute myelogenous leukemia, myelodysplastic syndrome, T-cell lymphoma, B-cell lymphoma, chronic lymphocytic leukemia, multiple myeloma, glioblastoma, gynecological cancers, lung cancer, head and neck cancer, sarcoma, melanoma, breast cancer, prostate cancer, colon cancer, pancreatic cancer, gastric cancer, esophageal cancer, salivary gland tumors	(>50 trials total). Lung cancer trials: NCT02536495, NCT02351505, NCT03095612, NCT02250885, NCT02213133
Verdinexor (KPT-335)	Karyopharm Therapeutics, Inc	Exportin-1	1	Antiviral agent (approved for canine lymphoma)	NCT02431364
KPT-8602	Karyopharm Therapeutics, Inc	Exportin-1	1/2	Relapsed refractory Multiple myeloma	NCT02649790